Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with
the development of targeted therapies for advanced disease and concomitant molecular …

Background Osimertinib is a recommended treatment for advanced non–small-cell lung
cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant …

Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …

Consolidation anti-programmed death-ligand 1 has become a new standard of care in
unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy …

Lung cancer is the second most common and the deadliest type of cancer worldwide.
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …

Background Concurrent epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐
TKI) with radiotherapy in patients with EGFR‐mutant unresectable stage III non‐small cell …

Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …

Non-small cell lung cancer without sensitive mutations entered the splendid era of
immunotherapy. This review aims to provide an evidence-based summary for …